Methods of treating ocular disorders by administering a VEGF-binding antibody covalently linked to a hyaluronic acid polymer
AssigneeGenentech, Inc.
InventorsAmin Famili, Germaine Fuh, Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal
Life of this patent
Estimating the term…
Abstract
The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
Claims22
A method of treating an ocular disorder, the method comprising administering an effective amount of an antibody conjugate comprising (i) an antibody that specifically binds to vascular endothelial growth factor (VEGF) and (ii) a hyaluronic acid (HA) polymer covalently attached to the antibody, wherein the HA polymer has a polydispersity index (PDI) of between 1.0 and 1.1, or a pharmaceutical composition thereof to a subject in need of such treatment.
A method for treating an ocular disorder, the method comprising administering an effective amount of a pharmaceutical composition to a subject in need of such treatment, wherein the pharmaceutical composition comprises an antibody conjugate comprising (i) an antibody that specifically binds VEGF and (ii) an HA polymer covalently attached to the antibody, wherein the HA polymer has a PDI of 1.05, and wherein the antibody comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO:
- 11 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO:
- 12.
A method for treating an ocular disorder, the method comprising administering an effective amount of a pharmaceutical composition to a subject in need of such treatment, wherein the pharmaceutical composition comprises an antibody conjugate comprising (i) an antibody that specifically binds VEGF and (ii) an HA polymer covalently attached to the antibody, wherein the HA polymer has a PDI of 1.05, and wherein the antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 48 or SEQ ID NO:
- 49 and (b) a light chain comprising the amino acid sequence of SEQ ID NO:
- 50.
Dependencies are inferred from the claim text.